hepatitis-c-virus

Documents about hepatitis-c-virus

• Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Chronic HCV and HBV Coinfection#969271ClinicalTrials.gov
• Efficacy Study to Evaluate the Effect of New Antiviral Drugs on HCV Infection.#992373ClinicalTrials.gov
• Expanded Access to Glecaprevir/ Pibrentasvir#826116ClinicalTrials.gov
• Computer-based Intervention for Alcohol-using HIV/HCV+ Women#836037ClinicalTrials.gov
• "Pharmacoepidemiological Evaluation of Autophagy Inhibition in Treatment of HCV Patients Resistant to Standard Therapy. Pilot Study"#872921ClinicalTrials.gov
• Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: The InC3 Study#684030eScholarship
• A Study to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir, and Ledipasvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection#846833ClinicalTrials.gov
• Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection#909636ClinicalTrials.gov
• A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study#993049ClinicalTrials.gov
• Phenotypic analysis of mutations at residue 146 provides insights into the relationship between NS5A hyperphosphorylation and hepatitis C virus genome replication#190298Ora Oxford University Research
• Impact of Antiviral Therapy Scale-Up Among People Who Inject Drugs in Scotland: Regional Evidence of Hepatitis C Virus Elimination.#319229NCBI PubMed Central
• Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment#856959ClinicalTrials.gov
• A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects#905184ClinicalTrials.gov
• A Long Term Follow-up Study in Participants Treated in a Preceding Phase 2 or 3 Study With a Regimen Containing Odalasvir and AL-335 With or Without Simeprevir for the Treatment of Hepatitis C Virus (HCV) Infection#894835ClinicalTrials.gov
• TMC435-TiDP16-C121: A Study Comparing 2 Tablet Formulations of TMC435 to an Established Capsule Formulation and Evaluating the Effect of Food on Blood Levels of TMC435#813664ClinicalTrials.gov
• TMC435-TiDP16-C125 - Study in Healthy Volunteers to Evaluate the Potential of TMC435 to Increase the Sensitivity of the Skin Towards Exposure to Sun Light#862467ClinicalTrials.gov
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy#876736ClinicalTrials.gov
• A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C Virus#1044726ClinicalTrials.gov
• Are there any non-invasive methods to predict liver fibrosis in children infected by hepatitis C virus rather than liver biopsy?#685550NCBI PubMed Central
• Antiretroviral Switch From Didanosine to Tenofovir in HIV/HCV Co-infected Patients#848092ClinicalTrials.gov
• TMC435-TiDP16-C119 - A Study Comparing 2 New Capsule Formulations of TMC435 to an Established Capsule Formulation and Evaluating the Respective Blood Levels of TMC435 Following Single Dose Administration#1047931ClinicalTrials.gov
• Hepatitis C virus transmission among people who inject drugs in rural United States: mathematical modeling study using stochastic agent-based network simulation.#1365NCBI PubMed Central
• Safety Study of Recombinant Interferon Variant(PEG-IFN-SA) to Treat HCV Disease#843227ClinicalTrials.gov
• Study of ANA773 in Healthy Volunteers and Patients With Hepatitis C Virus (HCV) to Assess Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD)#1047640ClinicalTrials.gov
• Proteasome activator and antigen-processing aminopeptidases are regulated by virus-induced type I interferon in the hepatitis C virus-infected liver#326559KOASAS: KAIST Open Access Self-Archiving System
• A study protocol for co-designing risk communication strategies for hepatitis C virus (HCV) testing among priority populations in Johannesburg district, Gauteng, South Africa.#662583NCBI PubMed Central
• Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection#875741ClinicalTrials.gov
• Associations of hepatitis C virus (HCV) antibody positivity with opioid, stimulant, and polysubstance injection among people who inject drugs (PWID) in rural U.S. communities#348440PubMed Central
• Interpersonal Dynamics and Health Behaviors among People who Inject Drugs#651666eScholarship
• Anti-CTLA-4 Human Monoclonal Antibody CP-675,206 in Patients With Advanced Hepatocellular Carcinoma#881022ClinicalTrials.gov
• Ledipasvir/Sofosbuvir Fixed-Dose Combination on Cerebral Metabolism and Neurocognition in Treatment-Naive and Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection#912911ClinicalTrials.gov
• Efficacy of PTX+IFN Alpha+ RBV on Hepatitis C Virus Coinfected HIV Patients#837841ClinicalTrials.gov
• A Follow-up Study to Assess Resistance to ABT-072 in HCV-infected Subjects Administered ABT-072 in Prior ABT-072 Studies#861338ClinicalTrials.gov
• Analyse des Einflusses von seltenen Codons auf das „Ribosome Pausing“ und die Effizienz der Translation und Replikation des Hepatitis C Virus#367552JLUpub
• Trauma-informed, Resilience-based Telehealth Intervention for Improving HIV Prevention and HCV Care for Persons Who Inject Drugs in the Deep South (Pilot Testing: Aim3)#841591ClinicalTrials.gov
• Performance characteristics of an electronic medical record alert system to identify hospitalised patients with active hepatitis C virus infection: a cross-sectional analysis from two large academic centres.#645390NCBI PubMed Central
• Pooled prevalence, risk factors and barriers to care for hepatitis C virus (HCV) in adults with serious mental illness (SMI): an updated systematic review and meta-analysis - protocol.#670915NCBI PubMed Central
• Frequent Longitudinal Sampling of Hepatitis C Virus Infection in Injection Drug Users Reveals Intermittently Detectable Viremia and Reinfection#642252eScholarship
• Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen#991991ClinicalTrials.gov
• Relationship between serum viral load and stages of hepatic fibrosis in patients with chronic hepatitis C virus infections in Plateau State, Nigeria: Relation entre la charge virale sérique et les stades de fibrose hépatique chez les patients atteints d'une infection chronique par le virus de l'hépatite C dans l'État de Plateau, au Nigéria#329007African Journals Online
• Association between neighborhood-level overall social vulnerability and cumulative incidence of reported hepatitis C virus infection in Los Angeles County from 2018 to 2023#1053138Europe PMC
• Higher risk of incident hepatitis C virus among young women who inject drugs compared with young men in association with sexual relationships: a prospective analysis from the UFO Study cohort#675885eScholarship
• Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)#851349ClinicalTrials.gov
• A Study to Assess the Absolute Bioavailability and Pharmacokinetics of Simeprevir (TMC435) Administered as Single Oral Doses of TMC435 and an Intravenous Microdose of [3H]-TMC435 in Healthy Male Patients#890928ClinicalTrials.gov
• Persistent neurocognitive decline in a clinic sample of hepatitis C virus-infected persons receiving interferon and ribavirin treatment#675828eScholarship
• Universal opt-out screening for hepatitis C virus (HCV) within correctional facilities is an effective intervention to improve public health#614695eScholarship